Shore Capital reissued their hold rating on shares of AstraZeneca plc (LON:AZN) in a research note published on Monday, Marketbeat.com reports.

Several other brokerages have also weighed in on AZN. Deutsche Bank AG lowered their price objective on AstraZeneca plc from GBX 5,700 ($74.94) to GBX 5,300 ($69.68) and set a buy rating for the company in a research report on Thursday, August 3rd. HSBC Holdings plc set a GBX 4,100 ($53.90) price objective on AstraZeneca plc and gave the stock a sell rating in a research report on Tuesday, August 8th. Sanford C. Bernstein set a GBX 5,780 ($75.99) price objective on AstraZeneca plc and gave the stock a buy rating in a research report on Monday, September 25th. Credit Suisse Group reiterated a neutral rating and issued a GBX 5,000 ($65.74) price objective on shares of AstraZeneca plc in a research report on Monday, June 19th. Finally, Barclays PLC reiterated an overweight rating and issued a GBX 6,300 ($82.83) price objective on shares of AstraZeneca plc in a research report on Wednesday, July 26th. Three equities research analysts have rated the stock with a sell rating, eight have issued a hold rating and eleven have assigned a buy rating to the company’s stock. The stock presently has an average rating of Hold and a consensus price target of GBX 5,113.55 ($67.23).

ILLEGAL ACTIVITY NOTICE: “Shore Capital Reaffirms “Hold” Rating for AstraZeneca plc (AZN)” was reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this piece on another domain, it was illegally copied and reposted in violation of United States and international copyright law. The original version of this piece can be viewed at https://www.thecerbatgem.com/2017/10/13/shore-capital-reaffirms-hold-rating-for-astrazeneca-plc-azn.html.

In other AstraZeneca plc news, insider Nazneen Rahman purchased 39 shares of the business’s stock in a transaction on Thursday, July 27th. The shares were bought at an average cost of GBX 4,370 ($57.45) per share, for a total transaction of £1,704.30 ($2,240.73).

About AstraZeneca plc

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.

Analyst Recommendations for AstraZeneca plc (LON:AZN)

Receive News & Stock Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related stocks with our FREE daily email newsletter.